Published in final edited form as:

Annu Rev Nutr. 2011 August 21; 31: 49–63. doi:10.1146/annurev-nutr-081810-160756.

The Role of MicroRNAs in Cholesterol Efflux and Hepatic Lipid Metabolism

Kathryn J. Moore, Katey J. Rayner, Yajaira Suárez, and Carlos Fernández-Hernando

Departments of Medicine and Cell Biology, Leon H. Charney Division of Cardiology and the Marc and Ruti Bell Vascular Biology and Disease Program, New York University School of Medicine, New York, NY 10016, USA

Abstract

miRNAs represent an elegant mechanism of post-transcriptional control of gene expression that serves to fine-tune biological processes. These tiny non-coding RNAs (20–22 nt) bind to the 3′ untranslated region of mRNAs, thereby repressing gene expression. Recent advances in the understanding of lipid metabolism have revealed that miRNAs, particularly miR-122 and miR-33, play major roles in regulating cholesterol and fatty acid homeostasis. miR-122, the most abundant microRNA in the liver, appears to maintain the hepatic cell phenotype and its inhibition decreases total serum cholesterol. miR-33, an intronic microRNA located with the SREBP-2 gene, regulates cholesterol efflux, fatty acid β -oxidation and HDL metabolism. These findings have highlighted the complexity of lipid homeostasis, and the important role that miRNAs play in these processes, potentially opening new avenues for the treatment of dyslipidemias.

Keywords

miR-33; miR-122; HDL; fatty acid β -oxidation

Cholesterol and Cardiovascular disease

Complications of atherosclerosis are the most common causes of death in Western societies (33). Among the many genetic and environmental risk factors that have been identified by epidemiologic studies, elevated levels of serum cholesterol are probably unique in being sufficient to drive the development of atherosclerosis in human and experimental animals, even in the absence of other known risk factors (33). Serum cholesterol is carried by several lipoprotein particles that perform the complex physiologic tasks of transporting dietary and endogenously produced lipids. Low-density lipoproteins (LDL) have an essential role as a vehicle for the delivery of cholesterol to the peripheral tissues. Increased LDL levels are associated with increased risk of cardiovascular disease. LDL is taken up by cells via LDL receptors that recognize an N-terminal domain of apo B-100. Lack of functional LDL receptors leads to a massive accumulation of LDL in the artery wall (33). Atherosclerotic lesions begin as fatty streaks underlying the endothelium of large arteries. Recruitment of macrophages and their subsequent uptake of LDL-derived cholesterol are the major cellular events contributing to fatty streak formation (33).

To maintain cholesterol homeostasis, excess cholesterol is effluxed from cells to apoA-1 acceptors via the ATP-binding cassette transporters, ABCA1 and ABCG1 (89). Lipid-poor pre-beta high-density lipoproteins (HDL), rich in apoA-1, are synthesized by the liver or

intestinal mucosa and released into circulation. ABCA1 facilitates the efflux of phospholipids and cholesterol to apoA-1 to generate nascent, discoidal HDL particles. Lecithin-cholesterol acyl transferase (LCAT) esterifies free cholesterol from pre-beta HDL, resulting in mature HDL, which acts as an acceptor of ABCG1-effluxed cholesterol. Ultimately HDL transports cholesterol esters to the liver by two pathways (89). The cholesteryl esters are either directly delivered to the liver by scavenger receptor class B type 1 (SR-B1) or transferred to apoB-containing lipoproteins (VLDL/LDL) through cholesteryl ester transfer protein (CETP) and then transported to the liver through the LDLr. In both cases, the cholesterol ester that is transported to the liver is secreted as bile acid. CETP exchanges cholesteryl ester from HDL for TG from apoB-containing lipoproteins; these TG are then hydrolyzed by hepatic lipases, regenerating small HDL particles and pre-beta HDL, which, in turn, are released into circulation as acceptors of free cholesterol. The whole process is termed reverse cholesterol transport (RCT) and is believed to contribute to HDL's protective role in the development of atherosclerosis.

Regulation of cellular cholesterol metabolism

Cellular cholesterol levels are maintained through a tightly regulated and complex mechanism that involves *de novo* biosynthesis, internalization of exogenous cholesterol and efflux of excess cholesterol. This coordinated process is regulated by ER-bound sterol regulatory element-binding proteins (SREBPs) (9, 48). The SREBP family of transcription factors consists of SREBP-1a, SREBP-1c and SREBP-2 proteins that are encoded by two unique genes, *Srebp-1* and *Srebp-2*. The *Srebp-1* gene generates two alternative spliced transcripts, *Srebp-1a* and *Srebp-1c*, which are transcribed from different promoters (9, 48).

The SREBPs differ in their tissue-specific expression, their target gene selectivity and the relative potencies of their *trans*-activation domains. SREBP1c regulates the transcription of genes involved in fatty acid metabolism, such as fatty acid synthase (FASN) (5-7). SREBP2 and SREBP-1a regulate transcription of cholesterol-related genes, such as 3-hydroxy-3-methylglutaryl coenzyme A (HMGCR) reductase, which catalyzes a rate limiting step in cholesterol biosynthesis, and the low-density lipoprotein receptor (LDLr), which imports cholesterol from the blood (9, 41, 69). The other major transcription factors that regulate cholesterol homeostasis are the liver X receptors (LXR), which regulate the response to cholesterol excess (96). LXR α and LXR- β are ligand-activated transcription factors of the nuclear hormone receptor family that are activated by endogenous oxidized metabolites of cholesterol (oxysterols). LXRs are activated in response to elevated cholesterol levels and induce the expression of proteins involved in cholesterol absorption, transport, excretion, and efflux, including ABCA1, ABCG1, ABCG5/8 and apoE (96). As described above, ABCA1 promotes cellular cholesterol efflux to apoA-1 and is also primarily responsible for initiating HDL formation in the liver (89, 96). ABCG1 mediates the cellular cholesterol efflux to HDL and ABCG5/8 promotes cholesterol excretion into bile (89, 96).

MicroRNAs

In addition to classical transcription regulators, a class of non-coding RNAs termed microRNAs (miRNAs) has emerged as critical regulators of gene expression acting predominantly at the post-transcriptional level. MicroRNAs are small (~22 nucleotide [nt]) RNA molecules, single stranded in the mature form, that regulate gene expression in metazoan animals, plants and protozoa (2, 4). Since their discovery in *C. elegans* (53, 77, 94) hundreds of miRNAs have been identified in animals, plants and viruses (6). The miRNAs identified to date are currently curated and annotated at miRBase, hosted by the Sanger Institute as a publicly available repository (<http://microrna.sanger.ac.uk/>). Bioinformatic predictions and experimental approaches indicate that a single miRNA may

simultaneously target more than a hundred mRNAs (27). miRNAs thus constitute a new layer of regulatory control over gene expression programs in many organisms. In fact, human miRNAs are predicted to control the activity of more than 30-60% of all protein-coding genes (24, 27, 36). miRNAs have been shown to be involved in a broad range of developmental and physiological processes, (2, 4, 10, 13, 22, 51, 59, 88); thus, their deregulation is closely linked to human diseases including cancer and heart disease and vascular disorders(1, 11, 13, 28, 90).

In the last decades, much effort and progress has been made in understanding the molecular mechanisms that regulate cholesterol metabolism and participate in the progression of cardiovascular diseases. miRNAs are emerging as important contributors to the molecular mechanisms underlying physiological homeostasis and disease. Further understanding how miRNAs are integrated into complex genetic networks that regulate lipid homeostasis and dysregulation may potentially reveal novel therapeutic targets in this area.

MicroRNA biogenesis and function

miRNAs are encoded in diverse regions of the genome including both protein-coding and non-coding transcription units. Approximately half of miRNAs are derived from non coding RNA transcripts, while the majority of the rest are located within introns of protein-coding genes, with a very small portion (~10%) encoded by exons of long non protein-coding transcripts (mRNA-like noncoding RNAs)(20, 79, 81). The production of the functional, ~22 nt mature miRNA involves multiple processing steps (**Figure 1**). The majority of animal miRNAs are transcribed by RNA polymerase II, as long (thousands of nucleotides) primary transcripts generating a stem-loop containing the primary miRNA (pri-miRNA) (2, 49). In addition, RNA polymerase III has been demonstrated to generate the transcript of a subset of miRNAs(7). The resultant pri-miRNA is then processed within the nucleus by the Microprocessor complex, which consists of a ribonuclease III (RNase III), called Drosha(54) and a RNA-binding protein DGCR8/Pasha(38). The Microprocessor complex require a variety of accessory cofactors including DEAD box RNA helicases p68 and p72, as well heterogeneous nuclear ribonucleoproteins (hnRNPs)(35), that may function to promote the fidelity, specificity, and/or activity of Drosha cleavage. The product of the Drosha cleavage event is a 70-100 nt hairpin-shaped precursor (pre-miRNA) that is transported to the cytoplasm via an Exportin-5 and Ran-GTP dependent mechanism (58). In most of mammalian miRNAs, including the majority of those encoded within introns, Drosha processing occurs co-transcriptionally, before splicing of host RNA (canonical pathway). However, there is a small subset of intronic miRNAs called “miRtrons” that circumvent the Drosha pathway (50, 65, 80). The lariat-debranching enzyme resolves the branch point to generate a pre-miRNA like hairpin that can be exported from the nucleus and further processed in the cytoplasm. The pre-miRNA is further processed to produce the ~22 nt long miRNA duplex (miRNA:miRNA*) by Dicer, another RNaseIII enzyme, which removes the terminal loop, yielding a ~22 nt RNA duplex (15, 42, 55).

Cleavage by Drosha and Dicer are not the only RNA processing events that miRNAs can go through during maturation. Adenosine deaminases that act on RNA (ADAR) catalyze the conversion of adenosine to inosine in dsRNA. Several studies have demonstrated that pri-miRNAs and pre-miRNAs are substrates of ADAR enzymes which prevents Dicer processing and results in the accumulation of pre-miRNA hairpins. This editing process occurs in a tissue specific manner and may underlie tissue-specific expression of some miRNAs(46, 95). It has been very recently shown that a subset of miRNAs, typified by the miR-144/451, are processed independently of Dicer in the cytoplasm. Instead, the secondary cleavage is carried out by Ago2, an Argonaute protein that is part of the complex that aligns the miRNA and messenger RNA (14, 16, 75). The precursor of these miRNAs possess a

stem that is uncommonly short (17 nucleotides), the mature miRNA (23 nucleotides) spans not only the length of the 5' arm of the stem but covers all of the loop sequence. These features are predicted to be insufficient for recognition by Dicer.

The fully processed miRNA duplex obtained via Dicer or Ago2 processing is unwound into the mature single-stranded form (guide strand) and its complementary strand (passenger strand or miRNA*). One of them will be selected and will associate with other members of the Ago protein family within the effector ribonucleoprotein complex RISC (RNA-induced silencing complex)(34, 35, 61, 70). The intrinsic features of the duplex will determine which strand is incorporated into RISC and become a mature miRNA(49, 86). The thermodynamic asymmetry of the miRNA duplex contributes to the strand selection (47, 82). The strand, whose 5' end is less stably base-paired, will be more frequently selected as the guide, while the other strand (miRNA*) will be excluded from the RISC and generally thought to be degraded. However, in some instances, the passenger strand may be selected and used in gene regulation (67). In fact, recent deep-sequencing efforts indicate that a large number of miRNA* are not degraded but rather associate to Ago1 or Ago2 (17, 31, 66, 67, 83). In this case both strands may be functional and indicate that miRNA precursors can also be bifunctional (17, 66, 67).

As part of the RISC, the mature miRNA guides the complex to its RNA target by Watson-Crick base-pairing interactions regulating protein synthesis (5). When there is a perfect or near-perfect complementarity to a site(s) in the 3' UTR of an mRNA, the target can be cleaved and degraded. However, in animals, most studied miRNAs pair imperfectly with their mRNA targets in the 3' UTR and inhibit expression of their targets mainly through translational repression or/ and mRNA decay (71). Recent studies have shown that miRNAs can also repress mRNA targets through binding to other regions including 5' UTRs or protein-coding exons (25, 60, 68, 78), and in some cases may even activate translation (39, 68, 91, 92). However, the mechanistic details of protein synthesis inhibition by miRNAs are not well understood. Potential pathways include sequestration from ribosomes (by relocation into P bodies), blockage of translational initiation, translational repression after initiation and target deadenylation coupled to transcript degradation (57, 71) (**Figure 1**). There have been several recent reviews covering these topics (5, 10, 13, 23, 24, 49, 73, 87).

The computational identification of miRNA targets and the validation of miRNA-target interactions represent fundamental steps in understanding the contribution of miRNAs in cell functions. Several bioinformatic tools have been developed to predict miRNA targets (5) and these algorithms collectively rely on several criteria (5). In mammals, the most important requirement of miRNA:target interaction, although not always essential, is a contiguous base pairing of the miRNA nt 2-8, representing the "seed" region (56). In many cases, the seed region seems to determine recognition. However in certain cases additional determinants are required, such as reasonable complementarity to the miRNA 3' half to stabilize the interaction (nt 13-16) to compensate for inconsistent binding in the seed region (3, 5, 37, 84). In addition, certain features of the 3' UTR sequences surrounding the target site may boost miRNA efficacy, such as AU-rich sequences and positioning at least 50 nt from the stop codon and away from the center of long UTRs (5, 37). Given the many criteria that influence miRNA targeting, it has become clear that the validation of predicted miRNA targets is crucial step in understanding potential (85)miRNA functions. As the understanding of miRNA binding biology increases, it can be expected that existing algorithms will become progressively more accurate.

Control of cholesterol metabolism by miRNAs

The elegance of microRNAs comes from their ability to simultaneously regulate the expression of many targets, allowing for the synchronized control of multiple genes in the same biological pathway. One such pathway is cholesterol metabolism, which has been shown to be regulated in different ways by the following miRNAs: miR-122, miR-370, miR-378/378*, miR-335, miR-125a-5p and miR-33. Among these, miR-122 was the first to be described for its role in regulating total serum cholesterol and liver metabolism, and has been the most widely studied liver miRNA. More recently however, other miRNAs have been shown to control a variety of aspects of lipid metabolism, from adipocyte differentiation to HDL biogenesis and cholesterol efflux.

miR-122 and liver metabolism

miR-122 is highly expressed by the liver, and its estimated to account for approximately 70% of all liver miRNA (68). It was first identified due to an unusual genetic rearrangement of c-myc found in a woodchuck liver tumor, which gave rise to a non-coding, hairpin structure that was later revealed to be the precursor for miR-122 (39). miR-122 is highly conserved, from humans to frogs, suggesting an important role for this miRNA that has been under selection pressure throughout evolution (32). Despite its high degree of conservation, and its abundance in the liver, the targets of miR-122 were first described to be those involved in the cellular response to stress and amino acid starvation, and at first did not appear to regulate normal hepatic physiology (12). It was only using inhibition strategies to target miR-122 in vivo that the physiological relevance of miR-122 was revealed. Esau et al. employed 2'-O-methoxyethyl phosphothioate (2'MOE) anti-sense oligonucleotides (ASO) in both normal and high-fat diet fed C57BL/6 mice for a period of 5 weeks, and examined the expression of predicted targets of miR-122, showing that miR-122 inhibition upregulated a number of predicted miR-122 targets, including ALDOA, GYS1, and CCNG1 (21). More importantly, using gene expression array analysis, the study revealed that silencing of miR-122 resulted in an upregulation of over 100 genes containing 7-8 nucleotide seed matches for miR-122 in their 3'UTR, and many of which had not been previously predicted based on bioinformatic prediction algorithms. Similarly, Elmen et al. used a complimentary strategy to identify miR-122 target genes, using locked-nucleic acid (LNA)-mediated antagonism of miR-122 in normal mice (19). Using gene expression arrays, they identified 199 genes that were upregulated by anti-miR122 that contained at least one miR-122 recognition sites. Taken together, these results imply that endogenous miR-122 is repressing a large number of genes that become derepressed when miR-122 is silenced. Functionally speaking, the consequences of silencing miR-122 in mice are a sustained reduction in total plasma cholesterol, observed in both the LDL and HDL fractions (19, 21). Furthermore, miR-122 antagonism in mice fed a high-fat diet resulted in a significant improvement in liver steatosis, as seen by the reductions in liver triglyceride content, and an increase in the rate of fatty acid β -oxidation (21). These results were consistent with the observation that miR-122 controls the expression of FASN, ACC1 and ACC2- all genes involved in fatty-acid synthesis and oxidation. The promising results from mouse studies prompted the use of LNA-antagomirs directed against miR-122 to be test in non-human primates (18, 52). Much like what was observed in mice, silencing of miR-122 in African green monkeys (18) and chimpanzees (52) resulted in substantial reductions in total plasma cholesterol, ranging from 20-30%, with no apparent toxicity or histopathological changes in the liver.

Certainly the targeting of miR-122 shows promise for the treatment disorders of lipid metabolism, but currently antagonism of miR-122 is being actively investigated for a therapeutic strategy in patients with hepatitis C infection. In addition to the target genes described above, miR-122 binds two positions the 5' noncoding region in the hepatitis C viral genome, and this binding is essential to viral accumulation and propagation in infected

hepatocytes (44, 45, 74). In non-human primates, silencing of miR-122 resulted in sustained reductions in HCV viremia and improvement in liver pathology, with no evidence of viral resistance (52). The safety and efficacy of anti-miR122 demonstrated in non-human primates prompted the first use of a miRNA-based therapeutic to enter phase 2 clinical trial. Miravirsin, by Santaris Pharma A/S, is an LNA-antagomir against miR-122, and is currently being tested in patients with hepatitis C infection (26). Phase I results in healthy subjects showed that Miravirsin is well tolerated, and the double-blind placebo controlled Phase 2 trial will certainly yield exciting results for the potential for miRNA-based therapeutics for the treatment of chronic diseases.

miR370 and its multifaceted regulation of lipid metabolism

Another miRNA, miR-370, has been described for its role in regulating cholesterol metabolism. miR-370 was first studied in a model of dominant-negative cJun overexpression, which was found to up-regulate miR-370 2.2-fold, and concomitantly downregulate carnitine palmitoyl transferase (Cpt1 α)- the rate limiting step in the fatty acid β -oxidation pathway (43). miR-370 directly targets Cpt1 α by binding target sequences in the 3'UTR, which results in downregulation of Cpt1 α expression, and consequently reduced fatty acid β -oxidation in culture hepatic cell lines. However, in addition to directly regulating genes involved in fatty acid metabolism, miR-370 regulates the expression of miR-122, which as described above, controls the expression of lipid and fatty acid metabolism. The authors demonstrate that over-expression of miR-370 leads to an upregulation of miR-122, and a resulting upregulation of lipogenic genes like SREBP-1c and DGAT2 (43). Although the mechanism of this reciprocal control of miRNA expression and the consequent upregulation of certain genes is still unclear, the study highlights the complexity and the multiple layers of miRNA-mediated modulation of lipid metabolism and how our current understanding is incomplete.

miR-378/378* in adipocyte lipid biogenesis

More recently, another miRNA was found to play a role in the regulation of lipid metabolism: miR-378/378*. The authors began by investigating the effect of Ago2 knockdown on adipocyte differentiation, and surprisingly found that Ago2 had very little effect on this process, suggesting miRNAs may not be strongly influencing this pathway. In contrast, during lipid droplet formation, Ago2 deletion had profound effects on the accumulation of triacylglycerol and phospholipids (29). This prompted the screening of miRNAs that are altered during adipogenesis *in vitro*, and of the few miRNAs that were altered by lipid content, miR-378/378* was most highly upregulated. Interestingly, miR-378/378* is located within the peroxisome proliferator-activated receptor gamma coactivator-1 beta (PGC1 β), and the two transcripts are co-transcribed during adipocyte differentiation (29, 87). Over-expression of miR-378/378* lead to increased lipid droplet size, and accumulation of triacylglycerol in 3T3-L1 adipocytes, without demonstrable effects on fatty acid β -oxidation. Moreover, over-expression of miR-378/378* resulted in increased triacylglycerol synthesis, whereas knockdown of miR-378/378* caused a decrease in triacylglycerol synthesis. In searching for possible targets of miR-378/378*, the authors performed a gene expression array, but surprisingly found that in response to over-expression of miR-378/378*, when target genes would be expected to be downregulated, there were eight sets of genes that were upregulated in response to miR-378/378*. These included genes involved in fatty acid synthesis (i.e. FAS, SCD-1, resistin), which would help to explain the increased triacylglycerol synthesis in the presence of miR-378/378*. Interestingly, none of the over 20 predicted targets of miR-378/378* that were tested were found to be true targets of this miRNA, and surprisingly there was an increase in the transcriptional activity of C/EBP α and β . The authors speculate that this could be an indirect effect, through the miR-378/378*-mediated downregulation of a transcriptional repressor of

the C/EBPs, or else could suggest that miR-378/378* is acting to enhance transcriptional activity of C/EBP α and β by an atypical mechanism. Although this hypothesis requires further study, it is clear that the miRNA-mediated regulation of adipocyte differentiation and adipogenesis is multifaceted and not as straightforward as it may first appear, representing another layer of complexity of miRNA regulation.

miR-33 regulates lipid metabolism

Recently, several groups independently reported that the SREBP-2 locus transcribes not only the mRNA for this transcriptional regulator of cholesterol uptake and synthesis, but also a highly conserved microRNA, miR-33a, that represses multiple genes involved in cellular cholesterol trafficking (63, 64, 76). miR-33a has been highly conserved during evolution and is present in the genomes of flies to vertebrates. Notably, a second isoform of miR-33, *miR-33b*, is found within *Srebf-1* in a more limited number of species (64). Although present in primates, miR-33b is absent in rodents, and to date has been less well studied than miR-33a. As has been reported for several intronic miRNAs, miR-33a and miR-33b are co-transcribed with their host genes under conditions that regulate SREBP-2 and SREBP-1, respectively. Interestingly, despite a two-nucleotide variation in the mature forms of miR-33a and miR-33b, these miRNAs similarly target a variety of lipid metabolism associated genes including *Abca1*, *Crot*, *Cpt1a*, *Hadhb*, and *Ampka*, suggesting overlapping functions (Davalos *et al.*, manuscript under revision).

Although the genomic location of miR-33a was reported in 2004, a number of years passed before the significance and the functional consequences of this location were established. Yet in a series of parallel studies published in 2010, miR-33 was identified as a key post-transcriptional regulator of cellular cholesterol homeostasis by three independent laboratories (63, 64, 76). Using an unbiased microarray approach, our group identified miR-33a as one of twenty microRNAs altered by cholesterol content in macrophages (76). Under cholesterol-depleted or cholesterol-enriched conditions, expression of miR-33 paralleled that of SREBP-2, suggesting that these genetic elements are co-regulated. Furthermore, we showed that dietary cholesterol alters hepatic miR-33 expression levels in vivo, in both normal and hypercholesteromic mice. Two other groups, Najafi-Shoushtari *et al.* and Marquardt *et al.*, uncovered the presence of miR-33 through *in silico* bioinformatic analysis of SREBP loci. These investigators also showed that *miR-33a* is co-transcribed along with *Srebf-2* in both hepatocytes and macrophages, and that the expression of *miR-33a* and *Srebf-2* is comparable across many tissues (63, 64).

Despite their different approaches, all three groups quickly honed in on the top predicted gene target of miR-33, the ATP-binding cassette transporter ABCA1 that is responsible for the movement of free cholesterol out of the cell. The 3'UTR of *Abca1* contains three highly conserved binding sites for miR-33a and/or miR-33b and the expression of ABCA1 mRNA and protein is strongly repressed by miR-33 overexpression in a variety of cell types (63, 64, 76). Analysis of the 3'UTR of *Abca1* revealed that the targeting by miR-33 is direct and specific, as mutations in these sites results in the relief of the repression of *Abca1* by miR-33 (63, 64, 76). Functionally, over-expression of miR-33 in macrophages and hepatocytes decreased cholesterol efflux to apoA1- a key step in the generation of HDL and reverse cholesterol transport (RCT). Moreover, the inhibition of endogenous miR-33 results in an increase in expression of ABCA1 protein, and a concomitant increase in cholesterol efflux to apoA1, indicating a physiological relevant role for this miRNA in regulating ABCA1 (63, 64, 76).

In addition to ABCA1, our study identified two other genes involved in cholesterol mobilization as targets of miR-33: ABCG1 (63, 76), which mobilizes cellular free

cholesterol to more lipidated HDL particles, and NPC1 (76), which transports cholesterol from lysosomal compartments to other parts of the cell in need (**Figure. 2**). Interestingly, miR-33 targeting of these two genes differs in mice and humans. The 3'UTR of the mouse *Abcg1* gene contains two miR-33 binding sites, however these sites are not conserved in the human 3'UTR. miR-33 overexpression in macrophages confirmed that miR-33 inhibits ABCG1 expression in cells of mouse but not human origin, indicating species-specific regulation of this gene by miR-33 (63, 76). The functional consequence of ABCG1 targeting in cells of mouse origin was demonstrated by a decrease in cholesterol efflux to HDL after over-expression of miR-33 (76). Furthermore, the 3'UTR of human *Npc1* contains two miR-33 binding sites, resulting in repression of NPC1 protein expression by miR-33 in human macrophages and hepatocytes. NPC1 acts in concert with ABCA1 to efflux cholesterol to apoA1 (93), indicating that miR-33 represses a second part of the cellular cholesterol export pathway in humans. However, the 3'UTR of mouse *Npc1*, which contains only one miR-33 binding site, is not repressed (76). Together, these results indicate that miR-33 targets multiple genes in the pathway regulating efflux of cholesterol to HDL.

miR-33 Regulates HDL levels *in vivo*

HDL plays a key role in the removal of excess cholesterol from the body through the reverse cholesterol transport (RCT) pathway. ABCA1 and ABCG1 have important functions in the RCT pathway: (1) In the liver, ABCA1 mediates the initial lipidation of apoA1 to form nascent HDL particles and (2) In peripheral tissues, particularly macrophages in atherosclerotic lesions, ABCA1 mediates the efflux of cellular cholesterol to this nascent HDL, while ABCG1 contributes to the further lipidation of HDL. The observations that miR-33 could reciprocally control ABCA1 and ABCG1 expression upon activation of SREBP-2 thus lead to the hypothesis that miR-33 may control HDL levels *in vivo*. Using a variety of approaches, from viral delivery of antisense oligonucleotides to locked nucleic acid (LNA) inhibitors, it was demonstrated that modulation of miR-33 levels *in vivo* alters hepatic ABCA1 protein expression and circulating HDL (63, 64, 76). *In vivo* overexpression of miR-33 decreased HDL levels by a 25%, whereas its inhibition increased circulating HDL by 25-30%. Notably, these experiments were performed in both normal and high-fat diet fed mice, indicating that inhibition of miR-33 results in a functional increase in HDL even when miR-33 (and SREBP-2) levels would be predictably low. Together these data indicate that anti-miR33 treatment to elevate ABCA1 levels and increase HDL levels holds promise for the treatment and/or prevention of coronary artery disease (CAD), in which an underlying risk factor is low levels of HDL.

Shortly after the demonstration that miR-33 regulates HDL levels *in vivo*, this finding was confirmed in a molecular genetic-causation study by Horie *et al.* These investigators generated mice in which miR-33 was deleted from the intron of SREBP-2, without affecting the expression of the host gene. These mice, which were viable and fertile, showed increased hepatic ABCA1 expression and a 25-40% increase in circulating HDL levels (40). Notably, whereas no differences in male and female mice were observed in studies using synthetic inhibitors, female miR33^{-/-} mice show larger increases in circulating HDL than their male counterparts. The molecular mechanisms of this difference are currently unknown. Interestingly, the increase in HDL in miR33^{-/-} mice appears to be in the larger, more lipidated HDL fractions, with no changes observed in the smaller HDL fractions (40). This increase in HDL particle size may be as a result of efflux of cholesterol to HDL from extrahepatic tissues into the reverse cholesterol transport pathway, where ABCA1 and ABCG1 plays important roles.

miR-33 Targets Genes Involved in Fatty Acid Metabolism

In addition to cholesterol transport, miR-33a and miR-33b were recently reported to target genes involved in the β -oxidation of fatty acids. We and others showed that miR-33 binding sites are highly conserved in the 3'UTR of *Cpt1a*, *Crot* and *Hadhb*, from humans to chicken ((30) and Davalos *et al.*, manuscript under revision). Each of these genes plays a distinct role in the fatty acid oxidation pathway: CPT1a is required for coupling of acetyl CoA to carnitine, allowing for transport of medium- and long- chain fatty acids to the mitochondria for β -oxidation (8, 62, 72). CPT1a is the rate-limiting step for this process, and is not surprisingly one of the most highly regulated members of the β -oxidation pathway (8, 62, 72). Similarly, CROT is a peroxisomal enzyme that is required for the coupling of short-chain fatty acids to carnitine, also transporting them into the mitochondria. Finally, HADHB is required for the last three steps in the β -oxidation pathway in the mitochondria (8, 62, 72). Analysis of the 3'UTR activity of *Cpt1a*, *Crot* and *Hadhb* revealed that miR-33 targets these genes in the fatty acid oxidation pathway, and over-expression of miR-33 in hepatocytes decreases CPT1a and HADHB protein expression.

Gerin *et al.* proposed that when SREBP-2 is activated, miR-33a would also target genes involved in cellular β -oxidation of fatty acids, which is known to occur during states of cholesterol depletion. Indeed, they demonstrated that overexpression of miR-33a reduced cellular fatty acid β -oxidation (30). While this group focused their studies on miR-33a, perhaps of greater interest is the role of miR-33b in this process, which is encoded within *Srebp-1*. SREBP1 is upregulated during states of insulin excess, when cellular fatty acid β -oxidation is reduced – possibly as a result of upregulation of miR-33b. Indeed, work from our group showed that activation of SREBP-1 with an LXR agonist leads to increased expression of miR-33b (Davalos *et al.*, manuscript under revision). Furthermore, we found that miR-33a and miR-33b similarly target the 3' UTR activity of *Crot*, *Cpt1a*, *Hadhb*, and *Ampk α* , indicating that both isoforms likely play a role in the regulation of these genes (Davalos *et al.*, manuscript under revision). Taken together, these data suggest that anti-miR-33 treatment may be a viable therapy for metabolic syndrome, in which both low HDL and hypertriglyceridemia are key contributors to the disease. The data to date indicate that inhibition of miR-33 would both increase HDL levels and fatty acid oxidation, however further *in vivo* testing of this in animal models will be challenging due to the lack of conservation of miR-33b in lower mammals such as mice.

Conclusions

It has become increasingly recognized that microRNAs play a prominent role in regulating biological processes. Although this field is still in its infancy in the area of lipid metabolism, there is little doubt that additional microRNAs will be identified in the near future that regulate lipid metabolism pathways. Many of these may have potential as targets for the treatment of metabolic disorders, but the development of such therapeutics faces numerous challenges, including target identification, specificity, mode of delivery and length of action. Perhaps most critical will be understanding the full range of targets that a specific miRNA or anti-miRNA affects. As an example, anti-miR-122 is in phase II clinical trials for the treatment of chronic HCV infection, however it remains unclear which direct targets of miR-122 account for its profound effects in the liver. Such an understanding may take years of basic research to untangle. Anti-miR-33 appears to hold promise as a therapy to raise HDL in the treatment of cardiovascular disease and metabolic syndrome. Studies of the effects of anti-miR-33 in animal models of atherosclerosis will undoubtedly be revealed shortly and will likely provide valuable information on the efficacy of such a treatment. The success of phase I clinical trials of anti-miR-122 and studies of this drug in primates are encouraging, and similar studies of anti-miR-33 are eagerly awaited.

GLOSSARY

microRNA	small non-coding RNA that post-transcriptionally inhibits gene expression
3' UTR	3' untranslated region of mRNA which frequently contains microRNA binding sites
SREBP	sterol response element binding proteins are transcription factors that regulate expression of lipid metabolism genes
Cholesterol efflux	the process whereby free cholesterol is exported from the cell
Fatty acid b-oxidation	
Anti-microRNA	anti-sense oligonucleotides that inhibit miRNA expression

ABBREVIATIONS/ACRONYMS

miRNA	microRNA
SREBP	sterol response element binding protein LXR: liver X receptor
HDL	high density lipoprotein
LDL	low density lipoprotein
HCV	hepatitis C virus
ABCA1	ATP-binding cassette transporter A1
ABCG1	ATP-binding cassette transporter G1
NPC1	Neimann Pick C1

REFERENCES

1. Alevizos I, Illei GG. MicroRNAs as biomarkers in rheumatic diseases. *Nat Rev Rheumatol*. 2010; 6:391–8. [PubMed: 20517293]
2. Ambros V. The functions of animal microRNAs. *Nature*. 2004; 431:350–5. [PubMed: 15372042]
3. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. *Nature*. 2008; 455:64–71. [PubMed: 18668037]
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004; 116:281–97. [PubMed: 14744438]
5. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009; 136:215–33. [PubMed: 19167326]
6. Berezikov E, Cuppen E, Plasterk RH. Approaches to microRNA discovery. *Nat Genet*. 2006; 38 Suppl:S2–7. [PubMed: 16736019]
7. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. *Nat Struct Mol Biol*. 2006; 13:1097–101. [PubMed: 17099701]
8. Brady PS, Ramsay RR, Brady LJ. Regulation of the long-chain carnitine acyltransferases. *FASEB J*. 1993; 7:1039–44. [PubMed: 8370473]
9. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. *Cell*. 1997; 89:331–40. [PubMed: 9150132]
10. Bushati N, Cohen SM. microRNA functions. *Annu Rev Cell Dev Biol*. 2007; 23:175–205. [PubMed: 17506695]
11. Catalucci D, Gallo P, Condorelli G. MicroRNAs in cardiovascular biology and heart disease. *Circ Cardiovasc Genet*. 2009; 2:402–8. [PubMed: 20031613]

12. Chang J, Nicolas E, Marks D, Sander C, Lerro A, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. *RNA Biol.* 2004; 1:106–13. [PubMed: 17179747]
13. Chang TC, Mendell JT. microRNAs in vertebrate physiology and human disease. *Annu Rev Genomics Hum Genet.* 2007; 8:215–39. [PubMed: 17506656]
14. Cheloufi S, Dos Santos CO, Chong MM, Hannon GJ. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. *Nature.* 2010; 465:584–9. [PubMed: 20424607]
15. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. *Nature.* 2005; 436:740–4. [PubMed: 15973356]
16. Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, et al. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. *Science.* 2010; 328:1694–8. [PubMed: 20448148]
17. Czech B, Zhou R, Erlich Y, Brennecke J, Binari R, et al. Hierarchical rules for Argonaute loading in *Drosophila*. *Mol Cell.* 2009; 36:445–56. [PubMed: 19917252]
18. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, et al. LNA-mediated microRNA silencing in non-human primates. *Nature.* 2008; 452:896–9. [PubMed: 18368051]
19. Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. *Nucleic Acids Res.* 2008; 36:1153–62. [PubMed: 18158304]
20. Erdmann VA, Szymanski M, Hochberg A, Groot N, Barciszewski J. Non-coding, mRNA-like RNAs database Y2K. *Nucleic Acids Res.* 2000; 28:197–200. [PubMed: 10592224]
21. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. *Cell Metab.* 2006; 3:87–98. [PubMed: 16459310]
22. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. *Nat Rev Cancer.* 2006; 6:259–69. [PubMed: 16557279]
23. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. *Annu Rev Biochem.* 2010; 79:351–79. [PubMed: 20533884]
24. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? *Nat Rev Genet.* 2008; 9:102–14. [PubMed: 18197166]
25. Forman JJ, Collier HA. The code within the code: MicroRNAs target coding regions. *Cell Cycle.* 2010; 9
26. Franciscus A. Hepatitis C Treatments in Current Clinical Development. *HCV Advocate.* 2010
27. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* 2009; 19:92–105. [PubMed: 18955434]
28. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. *Annu Rev Med.* 2009; 60:167–79. [PubMed: 19630570]
29. Gerin I, Bommer GT, McCoin CS, Sousa KM, Krishnan V, MacDougald OA. Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis. *Am J Physiol Endocrinol Metab.* 2010; 299:E198–206. [PubMed: 20484008]
30. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. *J Biol Chem.* 2010
31. Ghildiyal M, Xu J, Seitz H, Weng Z, Zamore PD. Sorting of *Drosophila* small silencing RNAs partitions microRNA* strands into the RNA interference pathway. *RNA.* 2010; 16:43–56. [PubMed: 19917635]
32. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. *J Hepatol.* 2008; 48:648–56. [PubMed: 18291553]
33. Glass CK, Witztum JL. Atherosclerosis. the road ahead. *Cell.* 2001; 104:503–16. [PubMed: 11239408]
34. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. *Cell.* 2005; 123:631–40. [PubMed: 16271387]
35. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, et al. The Microprocessor complex mediates the genesis of microRNAs. *Nature.* 2004; 432:235–40. [PubMed: 15531877]

36. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. *Nucleic Acids Res.* 2008; 36:D154–8. [PubMed: 17991681]
37. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. *Mol Cell.* 2007; 27:91–105. [PubMed: 17612493]
38. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev.* 2004; 18:3016–27. [PubMed: 15574589]
39. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, et al. microRNA-122 stimulates translation of hepatitis C virus RNA. *Embo J.* 2008; 27:3300–10. [PubMed: 19020517]
40. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. *Proc Natl Acad Sci U S A.* 2010; 107:17321–6. [PubMed: 20855588]
41. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest.* 2002; 109:1125–31. [PubMed: 11994399]
42. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. *Science.* 2001; 293:834–8. [PubMed: 11452083]
43. Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. *J Lipid Res.* 2010; 51:1513–23. [PubMed: 20124555]
44. Jopling CL, Schutz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. *Cell Host Microbe.* 2008; 4:77–85. [PubMed: 18621012]
45. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. *Science.* 2005; 309:1577–81. [PubMed: 16141076]
46. Kawahara Y, Zinshteyn B, Chendrimada TP, Shiekhattar R, Nishikura K. RNA editing of the microRNA-151 precursor blocks cleavage by the Dicer-TRBP complex. *EMBO Rep.* 2007; 8:763–9. [PubMed: 17599088]
47. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. *Cell.* 2003; 115:209–16. [PubMed: 14567918]
48. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. *Genes Dev.* 1996; 10:1096–107. [PubMed: 8654925]
49. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. *Nat Rev Mol Cell Biol.* 2009; 10:126–39. [PubMed: 19165215]
50. Kim YK, Kim VN. Processing of intronic microRNAs. *Embo J.* 2007; 26:775–83. [PubMed: 17255951]
51. Krutzfeldt J, Stoffel M. MicroRNAs: a new class of regulatory genes affecting metabolism. *Cell Metab.* 2006; 4:9–12. [PubMed: 16814728]
52. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. *Science.* 2010; 327:198–201. [PubMed: 19965718]
53. Lee RC, Feinbaum RL, Ambros V. The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell.* 1993; 75:843–54. [PubMed: 8252621]
54. Lee Y, Ahn C, Han J, Choi H, Kim J, et al. The nuclear RNase III Drosha initiates microRNA processing. *Nature.* 2003; 425:415–9. [PubMed: 14508493]
55. Lee Y, Hur I, Park SY, Kim YK, Suh MR, Kim VN. The role of PACT in the RNA silencing pathway. *Embo J.* 2006; 25:522–32. [PubMed: 16424907]
56. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell.* 2005; 120:15–20. [PubMed: 15652477]
57. Liu J. Control of protein synthesis and mRNA degradation by microRNAs. *Curr Opin Cell Biol.* 2008; 20:214–21. [PubMed: 18329869]

58. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. *Science*. 2004; 303:95–8. [PubMed: 14631048]
59. Lynn FC. Meta-regulation: microRNA regulation of glucose and lipid metabolism. *Trends Endocrinol Metab*. 2009; 20:452–9. [PubMed: 19800254]
60. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. *Proc Natl Acad Sci U S A*. 2007; 104:9667–72. [PubMed: 17535905]
61. Maniatakis E, Mourelatos Z. A human, ATP-independent, RISC assembly machine fueled by pre-miRNA. *Genes Dev*. 2005; 19:2979–90. [PubMed: 16357216]
62. Mannaerts GP, Van Veldhoven PP, Casteels M. Peroxisomal lipid degradation via beta- and alpha-oxidation in mammals. *Cell Biochem Biophys*. 2000; 32:73–87. Spring. [PubMed: 11330072]
63. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. *Proc Natl Acad Sci U S A*. 2010; 107:12228–32. [PubMed: 20566875]
64. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. *Science*. 2010; 328:1566–9. [PubMed: 20466882]
65. Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC. The mirtron pathway generates microRNA-class regulatory RNAs in *Drosophila*. *Cell*. 2007; 130:89–100. [PubMed: 17599402]
66. Okamura K, Liu N, Lai EC. Distinct mechanisms for microRNA strand selection by *Drosophila* Argonautes. *Mol Cell*. 2009; 36:431–44. [PubMed: 19917251]
67. Okamura K, Phillips MD, Tyler DM, Duan H, Chou YT, Lai EC. The regulatory activity of microRNA* species has substantial influence on microRNA and 3' UTR evolution. *Nat Struct Mol Biol*. 2008; 15:354–63. [PubMed: 18376413]
68. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. *Mol Cell*. 2008; 30:460–71. [PubMed: 18498749]
69. Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. *J Biol Chem*. 2000; 275:32379–82. [PubMed: 10934219]
70. Peters L, Meister G. Argonaute proteins: mediators of RNA silencing. *Mol Cell*. 2007; 26:611–23. [PubMed: 17560368]
71. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? *Trends Cell Biol*. 2007; 17:118–26. [PubMed: 17197185]
72. Ramsay RR, Gandour RD. Selective modulation of carnitine long-chain acyltransferase activities. Kinetics, inhibitors, and active sites of COT and CPT-II. *Adv Exp Med Biol*. 1999; 466:103–9. [PubMed: 10709633]
73. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. *Nat Rev Mol Cell Biol*. 2007; 8:23–36. [PubMed: 17183358]
74. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, et al. Cellular cofactors affecting hepatitis C virus infection and replication. *Proc Natl Acad Sci U S A*. 2007; 104:12884–9. [PubMed: 17616579]
75. Rasmussen KD, Simmini S, Abreu-Goodger C, Bartonicek N, Di Giacomo M, et al. The miR-144/451 locus is required for erythroid homeostasis. *J Exp Med*. 2010; 207:1351–8. [PubMed: 20513743]
76. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. *Science*. 2010; 328:1570–3. [PubMed: 20466885]
77. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, et al. The 21-nucleotide let-7 RNA regulates developmental timing in *Caenorhabditis elegans*. *Nature*. 2000; 403:901–6. [PubMed: 10706289]
78. Rigoutsos I. New tricks for animal microRNAs: targeting of amino acid coding regions at conserved and nonconserved sites. *Cancer Res*. 2009; 69:3245–8. [PubMed: 19351814]
79. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. *Genome Res*. 2004; 14:1902–10. [PubMed: 15364901]
80. Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. *Nature*. 2007; 448:83–6. [PubMed: 17589500]

81. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. *Proc Natl Acad Sci U S A*. 2007; 104:17719–24. [PubMed: 17965236]
82. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. *Cell*. 2003; 115:199–208. [PubMed: 14567917]
83. Seitz H, Ghildiyal M, Zamore PD. Argonaute loading improves the 5' precision of both MicroRNAs and their miRNA* strands in flies. *Curr Biol*. 2008; 18:147–51. [PubMed: 18207740]
84. Selbach M, Schwanhaussner B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. *Nature*. 2008; 455:58–63. [PubMed: 18668040]
85. Shin C, Nam JW, Farh KK, Chiang HR, Shkumatava A, Bartel DP. Expanding the microRNA targeting code: functional sites with centered pairing. *Mol Cell*. 2010; 38:789–802. [PubMed: 20620952]
86. Siomi H, Siomi MC. On the road to reading the RNA-interference code. *Nature*. 2009; 457:396–404. [PubMed: 19158785]
87. Siomi H, Siomi MC. Posttranscriptional regulation of microRNA biogenesis in animals. *Mol Cell*. 2010; 38:323–32. [PubMed: 20471939]
88. Suarez Y, Sessa WC. MicroRNAs as novel regulators of angiogenesis. *Circ Res*. 2009; 104:442–54. [PubMed: 19246688]
89. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. *Cell Metab*. 2008; 7:365–75. [PubMed: 18460328]
90. van Rooij E, Marshall WS, Olson EN. Toward MicroRNA-Based Therapeutics for Heart Disease: The Sense in Antisense. *Circ Res*. 2008; 103:919–28. [PubMed: 18948630]
91. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. *Science*. 2007; 318:1931–4. [PubMed: 18048652]
92. Vasudevan S, Tong Y, Steitz JA. Cell-cycle control of microRNA-mediated translation regulation. *Cell Cycle*. 2008; 7:1545–9. [PubMed: 18469529]
93. Wang MD, Franklin V, Sundaram M, Kiss RS, Ho K, et al. Differential regulation of ATP binding cassette protein A1 expression and ApoA-I lipidation by Niemann-Pick type C1 in murine hepatocytes and macrophages. *J Biol Chem*. 2007; 282:22525–33. [PubMed: 17553802]
94. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene *lin-14* by *lin-4* mediates temporal pattern formation in *C. elegans*. *Cell*. 1993; 75:855–62. [PubMed: 8252622]
95. Yang W, Chendrimada TP, Wang Q, Higuchi M, Seeburg PH, et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. *Nat Struct Mol Biol*. 2006; 13:13–21. [PubMed: 16369484]
96. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. *J Clin Invest*. 2006; 116:607–14. [PubMed: 16511593]

LIST OF CENTRAL POINTS

Two miRNAs have been identified as key regulators of lipid metabolism pathways: miR-122 and miR-33

miR-122

- miR-122 is the most highly expressed microRNA in the liver and appears to maintain the hepatic cell phenotype.
- Inhibition of miR-122 decreases total serum cholesterol in mice and primates.
- Anti-miR-122 is in phase II clinical trial development for the treatment of chronic HCV.

miR-33

- miR-33a and miR-33b are intronic microRNAs located within the SREBP-2 and SREBP-1 genes, respectively.
- miR-33a/b are co-regulated with their host genes.
- miR-33a/b coordinately target genes involved in cellular cholesterol export and fatty acid β -oxidation.
- inhibition or targeted deletion of miR-33 increases circulating HDL levels in mice.

Future issues

- Identification of novel microRNAs controlling lipid metabolism It is clear from the work to date that microRNAs can play a key role in regulating lipid metabolism pathways and there remains much to be discovered. In the coming years it is likely that the identification of novel microRNAs and their targets will provide insight into the complex network that regulates lipid homeostasis. One of the many challenges will be to fully characterize these emerging candidates and confirm their physiological relevance.
- Translation of basic research on microRNAs into therapeutics The development of miRNA-based therapeutics faces numerous challenges, including identification of the full spectrum of targets, and a better understanding of their specificity, persistence and length of action. The success of phase I clinical trials of anti-miR-122, along with the studies of this drug in primates, are encouraging, and suggest that it is not unlikely that anti-microRNA therapies may become viable therapeutics in the not so distant future.
- **The therapeutic potential of antagonizing miR-33** Anti-miR-33 appears to hold promise as a therapy to raise HDL, however several key questions remain to be answered. For example, is the HDL generated by anti-miR-33 treatment functional (ie. Can it promote cholesterol efflux)? Also, what is the impact of anti-miR-33 on atherosclerosis? Finally, as with anti-miR-122, understanding the full complement of miR-33 targets will be necessary before this can be tested therapeutically.

Figure 1.

miRNA biogenesis pathway. miRNAs are transcribed in the nucleus by RNA polymerase from independent miRNA genes located in polycistronic transcripts or introns of protein-coding genes into primary transcripts (pri-miRNAs). Pri-miRNAs are processed in two steps in the nucleus and cytoplasm by the RNase III type endonuclease Drosha and Dicer, respectively, in complexes with dsRNA-binding domains proteins, DGCR8 and TRBP as indicated. In the canonical pathway, Drosha-DGCR8 processes the transcript to a stem-loop-structured precursor (pre-miRNA). Alternatively miRtrons, a subset of miRNAs derived from introns, may be processed into pre-miRNAs by the spliceosome and the debranching enzyme. Both canonical miRNAs and miRtrons are exported to the cytoplasm via Exportin 5, where they are further processed by Dicer-TRBP to yield ≈ 20 -bp miRNA duplexes. One strand is selected to function as the mature miRNA and loaded into the RNA-induced silencing complex (RISC) containing components of the Argonaute family (Ago 1-4), while the partner miRNA* strand is preferentially degraded. A subset of miRNAs, exemplified by miR-451, are produced independently of Dicer through recognition by Ago2. The mature miRNA produced by these two mechanisms leads to translational repression or degradation of the target mRNA. Animal miRNAs usually show only partial complementarity to the target mRNA promoting translational repression (initiation and post initiation steps) or deadenylation coupled to exonucleolytic degradation of target mRNA. mRNAs repressed by deadenylation or at the translation-initiation step can be moved to P-bodies for either degradation or storage.

Figure 2.

miR-33 Regulates Fatty Acid Metabolism and Cholesterol Efflux Cellular stimuli that activate transcription of *SREBF-1* or *SREBF-2* (eg. Insulin or low-sterol, respectively) induce the co-transcription of miR-33b and miR-33a, respectively. These pri-miRNAs are sequentially processed by Drosha and Dicer, and loaded into the RNA-induced silencing complex (RISC). As a result of binding target sites in the 3'UTR, miR-33a/b simultaneously inhibit the expression of genes involved in fatty acid metabolism (CROT, CPT1a and HADHB) and cholesterol transport (ABCA1, ABCG1 and NPC1). The outcome of miR-33 targeting of these genes is reduced fatty acid β -oxidation, reduced cholesterol efflux and reduced lipidation of apoA1 and HDL particles.

Figure 3.

Therapeutic targeting of miR-33 and miR-122 in atherosclerosis Upon treatment with anti-miR33 inhibitors, hepatic miR-33 levels are reduced, resulting in increased expression of target genes ABCA1 and ABCG1 in the liver. This results in enhanced HDL biogenesis and an increase in circulating HDL which can promote reverse cholesterol transport from tissues, including from lesional macrophage foam cell macrophage. In addition, anti-miR-33 may directly target these lesional macrophages, upregulating ABCA1 and ABCG1 expression, further enhancing cholesterol removal from the plaque. Antagonism of miR-122, the most highly expressed miRNA in the liver, decreases circulating cholesterol, particularly LDL, via as yet unspecified mechanisms. Notably, anti-miR-122 also decreases propagation of Hepatitis C virus in the liver and is currently in clinical trial for this application.